{
  "name" : "dacemirror.sci-hub.se_journal-article_c99efcb280bcea22235008cc2777de00_donthamsetti2019.pdf",
  "metadata" : {
    "source" : "CRF",
    "title" : "Genetically Targeted Optical Control of an Endogenous G Protein- Coupled Receptor",
    "authors" : [ "Prashant C. Donthamsetti", "Johannes Broichhagen", "Vojtech Vyklicky", "Cherise Stanley", "Zhu Fu", "Meike Visel", "Joshua L. Levitz", "Jonathan A. Javitch", "Dirk Trauner" ],
    "emails" : [ ],
    "sections" : [ {
      "heading" : null,
      "text" : "Genetically Targeted Optical Control of an Endogenous G ProteinCoupled Receptor Prashant C. Donthamsetti, Johannes Broichhagen, Vojtech Vyklicky, Cherise Stanley, Zhu Fu, Meike Visel, Joshua L. Levitz,§ Jonathan A. Javitch, , Dirk Trauner,# and Ehud Y. Isaco * , , ,\nDepartment of Molecular and Cell Biology, University of California, Berkeley, California 94720, United States Department of Chemical Biology, Max Planck Institute for Medical Research, Jahnstraße 29, 69120 Heidelberg, Germany §Department of Biochemistry, Weill Cornell Medical College, New York, New York 10024, United States Departments of Psychiatry & Pharmacology, Columbia University, New York, New York 10032, United States Division of Molecular Therapeutics, New York State Psychiatric Institute, New York, New York 10032, United States #Department of Chemistry, New York University, New York, New York 10003, United States Helen Wills Neuroscience Institute, University of California, Berkeley, California, 94720, United States Molecular Biophysics & Integrated Bioimaging Division, Lawrence Berkeley National Laboratory, Berkeley, California 94720, United States\n*S Supporting Information\nABSTRACT:G protein-coupled receptors (GPCRs) are membrane proteins that play important roles in biology. However, our understanding of their function in complex living systems is limited because we lack tools that can target individual receptors with su cient precision. State-of-the-art approaches, including DREADDs, optoXRs, and PORTL gated-receptors, control GPCR signaling with molecular, cell type, and temporal speci city. Nonetheless, these tools are based on engineered non-native proteins that may (i) express at nonphysiological levels, (ii) localize and turnover incorrectly, and/or (iii) fail to interact with endogenous partners. Alternatively, membrane-anchored ligands (t-toxins, DARTs) target endogenous receptors with molecular and cell type speci city but cannot be turned on and o . In this study, we used a combination of chemistry, biology, and light to control endogenous metabotropic glutamate receptor 2 (mGluR2), a Family C GPCR, in primary cortical neurons. mGluR2 was rapidly, reversibly, and selectively activated with photoswitchable glutamate tethered to a genetically targeted-plasma membrane anchor (membrane anchored Photoswitchable Orthogonal Remotely Tethered Ligand; maPORTL). Photoactivation was tuned by adjusting the length of the PORTL as well as the expression level and geometry of the membrane anchor. Our ndings provide a template for controlling endogenous GPCRs with cell type speci city and high spatiotemporal precision.\nINTRODUCTION G protein-coupled receptors (GPCRs) represent the largest superfamily of membrane proteins (>800 members).1 They respond to diverse stimuli (e.g., light, chemicals, peptides) and regulate a wide range of biological functions.1 Elucidating the roles of individual GPCRs is of profound importance for understanding physiological processes as well as pathological states in which GPCRs and/or their endogenous ligands are dysregulated. Moreover, GPCRs are targets of 25% of all currently available medications,2 and thus their characterization may shed light on mechanisms of drug action and enable the development of superior therapeutic strategies.\nGPCRs are spatially organized and temporally activated in a complex manner in living systems (especially the brain), making it di cult to interrogate individual receptors with\nsu cient precision. Each GPCR can exist and have distinct roles in more than one location. Not only can a receptor be found in di erent organs and tissues, it can also be expressed in neighboring but distinct cell types within the same area. GPCRs can also be turned on and o by their endogenous ligands in hundreds of milliseconds to tens of seconds.3 5\nMoreover, the precise temporal dynamics of GPCR activation can govern how a receptor controls downstream signaling processes and physiology.6,7\nTraditional approaches that target GPCRs, including pharmacology (chemical antagonists, agonists, allosteric modulators) and genetics (knockouts, overexpression), face\nReceived: March 28, 2019 Published: June 24, 2019\nArticle\npubs.acs.org/JACSCite This:J. Am. Chem. Soc.XXXX, XXX, XXX XX\n' XXXX American Chemical Society A DOI:10.1021/jacs.9b02895 J. Am. Chem. Soc.XXXX, XXX, XXX XXX\nD ow\nnl oa\nde d\nvi a\nU N\nIV O\nF SO\nU T\nH E\nR N\nI N\nD IA\nN A\no n\nJu ly\n1 7,\n2 01\n9 at\n1 4:\n15 :0\n9 (U\nT C ). Se e ht tp s: //p ub s. ac s. or g/ sh ar in gg ui de lin es f or o pt io ns o n ho w to le gi tim at el y sh ar e pu bl is he d\nar tic\nle s.\nchallenges of limited molecular, cell type, and/or spatiotemporal speci city. Thus, considerable e ort has gone into the development of engineered GPCRs that can be turned on and o in genetically de ned-cell types and locations. These approaches have employed chemogenetics (GPCRs designed to only respond to synthetic chemicals that do not existin vivo; DREADDs8) or optogenetics (chimeric GPCRs consisting of a partial sequence of a receptor of interest and the transmembrane portion of the naturally light-sensitive components of rhodopsin; optoXRs9 11).\nDREADDs and optoXRs require substantial modi cation to the receptor sequence, which may limit their physiological relevance (e.g., in both cases the receptor is no longer able to bind its endogenous ligand). In contrast, we devised a photopharmacological approach that can be used to control full length, near-native GPCRs.12 15 We used the latest iteration of this approach, Photoswitchable Orthogonal Remotely Tethered Ligands (PORTLs), to rapidly and reversibly photoactivate metabotropic glutamate receptors (mGluRs), which are Family C GPCRs.14,15 We rst synthesized a family of PORTLs that contain a receptor ligand (glutamate), an azobenzene moiety that rapidly photoisomerizes between itstrans-and cis-isomers with speci wavelengths of light, as well as a benzylguanine (benzylguanine-azobenzene-glutamate; BGAG;Figures 1A andS1). The PORTL is covalently tethered via its benzylguanine to a genetically encoded SNAP-tag that we fused directly to the Nterminus of the receptor (SNAP-mGluR;Figure 1B). Several aspects of the PORTL approach are critical to its design. First,\nthe glutamate moiety of BGAG was placed ush to the azobenzene (Figure 1A) so that it sterically binds the receptor in only one photoisomeric state (cis but not trans), thus allowing the PORTL to turn on and o the receptor in a lightdependent manner (Figure 1B). Second, tethering the PORTL\na ords selectivity by increasing its local concentration at the\nreceptor while preventing its binding to o -target proteins.\nThird, because the PORTL is attached to SNAP-tag and is\ntherefore remote from its binding site in the receptor, a long\nchemical linker was used to provide additional reach (Figure\n1A and B). Finally, the SNAP-tagged receptor is genetically\nencoded and thus can be targeted to de ned cell types.\nPORTLs and the other engineered tools discussed above are a powerful means to control GPCR signaling in living systems. However, they all require modi cation to a GPCR s sequence that may alter receptor function and therefore provide an incomplete and possibly inaccurate view of its physiological role. Moreover, the delivery of these tools necessitates nonphysiological receptor overexpression or costly and timeconsuming genetic knock-in. Taking this into consideration, we sought to develop a strategy to control GPCRs with as much precision as that a orded by existing methods, but in a manner that does not modify the receptor, i.e., an approach that targets endogenous receptors.\nEndogenous ion channels16 and more recently GPCRs17\nhave been targeted for selective pharmacological control using genetically encoded membrane-anchored peptidic ligands (ttoxins), which interact with their target protein as a result of a random encounter within the plasma membrane and high ligand a nity.18 This approach was recently adapted to block receptors that bind chemical ligands; that is, a HALO-tag was anchored to the plasma membrane and conjugated to a receptor antagonist (DARTs).19 Although t-toxins and DARTs can be targeted selectively to a desired cell type, once applied\nthey act persistently until removed from the plasma membrane by the cell. To address this limitation, an ion channel t-toxin was recently engineered with a light-sensitive LOV domain (LumiToxin),20 enabling it to partially block channel activity in a reversible manner. Although the LumiToxin design could in principle be applied to peptide binding-GPCRs, it is not suitable for the large number of receptors that bind chemical ligands.21 Moreover, the reversal kinetics of LOV domains are slow20 compared to the millisecond to second time scales of fast and slow synaptic events.\nIn this study, we developed a system that combines the membrane anchor of a DART with the photoswitchable control of a PORTL to enable genetically targeted, reversible activation of a GPCR. We applied the approach to wildtype mGluR2 (mGluR2-WT), which plays important roles in brain circuits and is a putative target for the treatment of schizophrenia.22 Instead of tethering BGAG as a PORTL directly to an engineered version of the receptor (SNAPmGluR;Figure 1B), we tethered it to a di usible, membrane anchored SNAP-tag (membrane anchored Photoswitchable Orthogonal Remotely Tethered Ligand; maPORTL;Figure\nFigure 1.Targeting modi ed and unmodi ed, native mGluRs with BGAG. (A) Benzylguanine-azobenzene-glutamate (BGAG) with a polyethylene glycol (PEG) linker of varying lengths between benzylguanine (BG) and azobenzene-glutamate. X denotes distinct spacer elements within di erent analogs of BGAG. Refer toFigure S1 for full chemical structures. (B) mGluRs consist of a ligand binding domain (LBD), cysteine rich domain (CRD), and transmembrane domain (TMD). Photoisomerizable BGAG reversibly activates an mGluR with light when bound to a SNAP-tag fused to the receptor s LBD. (C) The active isomer of BGAG,cis-BGAG, tethered to a SNAP-tag fused to a single-pass transmembrane segment (SNAPTM) randomly collides with and photoactivates a native (unmodi-\ned) mGluR.\nDOI:10.1021/jacs.9b02895 J. Am. Chem. Soc.XXXX, XXX, XXX XXX B\n1C). We optimized mGluR2-WT photoactivation with the maPORTL in HEK293T cells by adjusting (i) the chemical length of the BGAG linker, (ii) the positioning of the SNAPtag relative to the plasma membrane, and (iii) the surface density membrane anchored SNAP-tag. The photoactivation of the unaltered, native receptor by BGAG tethered to a membrane anchor (the maPORTL) is as e ective as that achieved by BGAG attached directly to the receptor. Furthermore, we demonstrate that the maPORTL selectively photoactivates endogenousmGluR2 in primary cortical neurons. Thus, the combination of genetic targeting of a membrane anchor and optical control of a tethered ligand gives the maPORTL approach the properties needed for the rapid, reversible, cell type speci c, and spatially de ned control of endogenous GPCRs in native tissue (ex vivoandin vivo). The maPORTL approach should be generally applicable to membrane proteins that are regulated by extracellular ligands.\nRESULTS AND DISCUSSION Development of a Membrane Anchored SNAP-tag.\nThe maPORTL approach requires a membrane anchored SNAP-tag. To accomplish this, we fused SNAP-tag to a singlepass transmembrane segment (TM) to generate SNAP-TM. The TM was taken from low density lipoprotein receptor (LDLR), which supports structured extracellular elements with a single TM.23\nFor an maPORTL to control its target receptor, the photoswitchable ligand must reach from its anchor point in SNAP-TM to the receptor s ligand binding site (Figure 1C). mGluR2-WT is an obligatory dimer that binds glutamate in its extracellular ligand binding domain (LBD), resulting in conformational changes in the cysteine rich and transmembrane domains (CRD and TMD, respectively) that facilitate G protein binding and activation (Figure 1B).24,25 Thus, photoactivation of mGluR2-WT by SNAP-TM:BGAG is expected to require that (i) SNAP-TM is located in the same place that canonical receptor activation occurs (the plasma membrane), and (ii) the SNAP-tag of SNAP-TM is on the same face of the membrane as the LBD of mGluR2-WT (extracellular). To assess the cellular distribution of SNAPTM, we labeled SNAP with the membrane permeant dye BGTMR. We found that a large fraction of SNAP-TM resides on the plasma membrane (Figure S2A). We next labeled cells with the membrane impermeant dye BG-Alexa647 (Figure S2B), which con rmed that SNAP-tag is present on the extracellular face of the plasma membrane.\nWe hypothesized that because mGluR2-WT and SNAP-TM likely interact by random collision rather than through a speci c interaction, SNAP-TM would need to be expressed in stoichiometric excess of mGluR2-WT in order for BGAG to be at a su cient concentration to e ciently photoactivate the receptor. We estimated the relative ratio of mGluR2 and\nSNAP-TM by measuring BG-Alexa647 labeling of cells\nexpressing SNAP-mGluR2 or SNAP-TM (Figure S2C). Our\nmeasurements indicated that surface expression of SNAP-TM\nis 3-fold higher than the receptor (one-way ANOVA, Tukey,\np < 0.0001).\nmGluR2-WT Photoactivation by the maPORTL Depends on the Length of the Photoswitchable Ligand.\nTo measure agonist-induced activation of mGluR2, we used a\nGi/o-mediated G protein-gated inwardly rectifying potassium\nchannel (GIRK) activation assay,12 whereby receptor activa-\ntion evokes an inward current that is measured using whole-\ncell, voltage clamp recordings (Figure S3). We employed BGAGs containing either zero, 12, or 28 polyethylene glycol (PEG) repeats between the benzylguanine and azobenzene glutamate moieties (BGAG0, BGAG12, or BGAG28; Figures S1 a d 2A). The BGAGs switch from thetrans to cis isomer con guration in response to illumination with near-UV light (380 nm) and vice versa with visible cyan light (500 nm).14,15 Photoswitching either BGAG0 or BGAG12 tethered to SNAPTM did not have a measurable e ect on mGluR2-WT (compared to 1 mM glutamate: 1 – 1%,n = 4, and 1– 1%,n = 4, respectively;Figure 2B and D). However, switching from the trans to cis in BGAG28 resulted in weak partial mGluR2-WT activation (13– 1% of 1 mM glutamate,n = 4)\nC\nthat was reversed by switching back to thetransisomer (Figure 2B and D). We asked whether BGAG28 is more e cacious at mGluR2-WT because it binds SNAP-TM more e ciently than BGAG0 or BGAG12. However, there was no signi cant di erence in the ability of the BGAGs to attach to SNAPTM when compared to the binding of the uorescent dye BGAlexa647 (one-way ANOVA;Figure S4).\nThere was a striking contrast between the e ect of linker length when BGAG was tethered to SNAP-TM and gated a separate mGluR2-WT protein versus when BGAG was tethered directly to SNAP-mGluR2. Consistent with our previous ndings, when BGAG0 and BGAG12 were tethered directly to SNAP-mGluR2, they photoactivated the receptor to a similar degree (42– 4% and 43– 4% of 1 mM glutamate,n = 8 and 7, respectively, one-way ANOVA, Tukey,p > 0.5; Figure 2C and D). However, when BGAG28 was tethered directly to SNAP-mGluR2, it was signi cantly less e ctive (13 – 4% of 1 mM glutamate,n = 8, one-way ANOVA, Tukey,p < 0.0001;Figure 2C and D). Thus, the BGAG with the longest linker was the weakest photoagonist of SNAP-mGluR2, yet it was the only compound that activated mGluR2-WT when tethered to SNAP-TM.\nBGAG can activate SNAP-mGluR2 even with the shortest linker (zero PEGs;Figure 2), suggesting that the SNAP-toLBD distance in this receptor is relatively short (Figure 1B). As BGAG gets longer, it explores a wider 3-dimensional space that results in a lower e ctive concentration of its glutamate moiety.11 Thus, the BGAG with the longest linker (28-PEGs) is associated with the weakest photoactivation of SNAPmGluR2 (Figure 2). However, for BGAG to reach between two proteins (i.e., from an anchored SNAP-tag adjacent the plasma membrane to the glutamate binding site in the extracellular receptor LBD;Figure 1C), its linker must be longer: the only BGAG to work at all was that with the longest linker (Figure 2).\nmGluR2-WT Photoactivation Is Enhanced by Inserting a Lift Peptide into the Membrane Anchor. We hypothesized mGluR2-WT photoactivation would be enhanced by bringing SNAP-tag and its bound BGAG closer to the LBD of mGluR2-WT. To accomplish this, we generated a series of SNAP-TM variants with lift peptides of varying lengths and physical properties inserted between the SNAP-tag and the TM. These included a exible linker (GGGGS), a rigid -helical linker (EAAAK), three repeats of the rigid linker (EAAAK)3,\n26 and a much larger spacer element consisting of the uorescent protein mVenus followed by an EAAAK linker (mVenus-EAAAK;Figure 3A).\nPhotoactivation with BGAG28 tethered to SNAP-EAAAKTM (SNAP-EAAAK-TM:BGAG28) was signi cantly greater than with the SNAP-TM that lacked a lift peptide (one-way ANOVA, Tukey,p < 0.05;Figure 3C and F), the greatest\noverall among the SNAP-TM variants (Figure 3F), and not signi cantly di erent from BGAG0 attached directly to SNAPmGluR2 (unpairedt test, p = 0.34). Notably, photoactivation with SNAP-EAAAK-TM:BGAG28 was 2-fold higher than that with GGGGS (one-way ANOVA, Tukey,p < 0.05;Figure 3F), suggesting that the rigid linker is better than the exible linker\nat stabilizing the SNAP:BGAG complex in a position that is\nappropriate for receptor activation.\nPhotoactivation by SNAP-TM variants with greater lift was either weak [(EAAAK)3; 10 – 2% of 1 mM glutamate,n = 3; Figure 3D and F] or not observable (mVenus-EAAAK; 1 – 2% of 1 mM glutamate,n = 3; Figure 3E and F), suggesting that BGAG must be optimally positioned above the plasma membrane. To test this further, we combined the longer SNAP-TM variants, SNAP-(EAAAK)3-TM and SNAP-mVe-\nFigure 3.Photoactivation depends on the properties of the peptide linker in SNAP-TM. (A) SNAP-TM variants with di erent lift peptides. (B E) Representative trace of BGAG28-induced photoactivation of mGluR2-WT when tethered to (B) SNAP-GGGGS-TM, (C) SNAP-EAAAK-TM, (D) SNAP-(EAAAK)3-TM, or (E) SNAPmVenus-TM. (F) Summary of photoactivation of mGluR2-WT with SNAP-TM variants tethered to BGAG28. one-way ANOVA, Tukey,*p < 0.05,** p < 0.01.\nDOI:10.1021/jacs.9b02895 J. Am. Chem. Soc.XXXX, XXX, XXX XXX D\nnus-EAAAK-TM, with the shorter BGAG analogs BGAG0 and BGAG12. In both cases, the most e ective photoagonist was BGAG12, not BGAG28 (Figure S5).\nBGAG must be a minimal length to be able to reach from its anchor point in SNAP-TM at the plasma membrane to its extracellular binding site in the mGluR2-WT LBD (Figure 2). Extending the maPORTL by inserting a lift peptide into SNAP-TM brings BGAG closer to the LBD, increasing its e ective concentration (Figure 3). However, further increasing the length of the maPORTL is eventually counterproductive (Figure S5) because the larger 3-dimensional space explored by the ligand results in a lower e ective concentration.\nmGluR2-WT Photoactivation with the maPORTL Is Rapid, Reversible, and Repeatable.Consistent with the photophysical properties of typical azobenzenes,27 photoactivation with SNAP-EAAAK-TM:BGAG28 was bistable (Figure 4A); that is, a short ash of near-UV light triggered persistent activation, and a short ash of cyan light triggered persistent deactivation. The kinetics of activation and deactivation were rapid (Figure 4B). Moreover, photoactivation could be reversed and repeated with no signi cant loss in magnitude after multiple cycles (n = 3, RM one-way ANOVA, p = 0.64;Figure 4C and D). Thus, like DARTs, maPORTLs can be used to persistently ligand a target receptor, mimicking the actions of drugs as well as pathological states. In addition, unlike DARTs, maPORTLs can also be reversibly turned on and o , a feature that can be used to mimic the actions of endogenous ligands such as glutamate that rapidly rise and fall in concentration in living systems.\nmGluR2 Photoactivation Is Limited by the Density of the maPORTL.We improved mGluR2-WT photoactivation by adjusting the positioning of the maPORTL at the cell surface (Figures 2and3). However, even the most e ective\nmaPORTL, SNAP-EAAAK-TM:BGAG28, only partially activated the receptor (Figure 3). One possibility is that the maPORTL is a partial agonist relative to glutamate. Alternatively, the maPORTL could be a full agonist that is at too low of a density at the plasma membrane to fully occupy the receptor. The activation of an mGluR2 dimer is a cooperative process, whereby the binding of one glutamate activates very partially and two glutamates more than double the activation.28 30 Thus, full receptor activation is expected to require that the dimer simultaneously binds two SNAPTM:BGAG complexes.\nTo determine whether mGluR2-WT photoactivation is limited by partial agonism or partial occupancy, we photoactivated the receptor with SNAP-EAAAK-TM:BGAG28 in the presence of an EC50 concentration of glutamate (1 M; Figures S6A and B). A partial photoagonist that fully occupies the receptor is expected to compete with and possibly inhibit 1 M glutamate-induced mGluR2-WT activation, whereas a full photoagonist that partially occupies the receptor should further activate it. SNAP-EAAAK-TM:BGAG28 was able to photo-\nactivate mGluR2-WT even in the presence of 1 M glutamate\n(Figure S6C), indicating that photoactivation is limited\nbecause some receptors are not occupied or are only partially\noccupied by ligand.\ning the Density of the maPORTL at the Plasma\nMembrane. We sought to enhance photoactivation with the\nmaPORTL approach by increasing the availability of BGAG,\nanalogous to when we doubled the number of azobenzeneglutamates directly tethered to mGluR2.15 To accomplish this, we generated a SNAP-TM variant with two SNAP-tags in tandem (tSNAP-EAAAK-TM) (Figure 5A) so that two BGAGs attached to a single anchor could simultaneously bind and thus fully activate the receptor. We also sought to increase the density of SNAP-TM at the cell surface by increasing its export from intracellular membranes (Figure S2A) to the plasma membrane. We added to the C-terminus of SNAP-EAAAK-TM andtSNAP-EAAAK-TM an endoplasmic reticulum export motif that was taken from the potassium channel Kir2.1 (tSNAP-EAAAK-TM-ERE;Figure 5A). This motif has been shown to enhance surface expression when transplanted into other membrane proteins, including halorhodopsin.31\nWe rst tested whether these modi cations resulted in a greater number of SNAP-tags on the plasma membrane. Cells expressing variants of SNAP-TM were labeled with the membrane impermeant uorescent dye BG-Alexa647. Compared to SNAP-TM and SNAP-EAAAK-TM, uorescence was higher withtSNAP-EAAAK-TM ( 2-fold), SNAP-EAAAKTM-ERE ( 2-fold), andtSNAP-EAAAK-TM-ERE ( 4-fold;n = 10, one-way ANOVA, Tukey,p < 0.05; Figure 5C), indicating an increase in the number of SNAP-tags at the cell surface and thus the available binding sites for BGAG. There was no signi cant di erence in cell viability between the SNAP-TM variants (n = 3, one-way ANOVA, Tukey,p > 0.05; Figure S7). Furthermore, survival was greater than 95% (Figure S7), indicating that the membrane anchor is well tolerated in cells.\nPhotoactivation of mGluR2-WT progressively increased with increasing levels of surface SNAP-tag (Figure 5D H). The greatest photoactivation of mGluR2-WT overall was observed withtSNAP-EAAAK-TM-ERE:BGAG28 (69 – 8% of 1 mM glutamate,n = 6;Figures 5G and H), which was 2-fold\nDOI:10.1021/jacs.9b02895 J. Am. Chem. Soc.XXXX, XXX, XXX XXX E\ngreater than that with SNAP-EAAAK-TM:BGAG28 (one-way ANOVA, Tukey,p < 0.01; Figures 5G and H). Notably, photoactivation withtSNAP-EAAAK-TM-ERE:BGAG28 also exceeded what was achieved with BGAG0 attached directly to SNAP-mGluR2 ( 2-fold; one-way ANOVA, Tukey,p < 0.05; Figure 5G). Overall, these results indicate that increasing the number of SNAP-tags fused to the TM as well as the surface expression of SNAP-TM enhances photoactivation of mGluR2-WT. maPORTL Photoactivation Is Selective for mGluR Subtype. PORTLs are selective because they are physically restricted to their target receptor (Figure 1B). In contrast, maPORTLs are not constrained to any given membrane protein. Thus, the degree of receptor selectivity of the maPORTL approach is expected to depend on the binding properties of the photoswitchable ligand and its positioning relative to the receptor binding site. Because the SNAP-TM:BGAG maPORTL contains glutamate, it could also act on other mGluRs, some of which may be\nFigure 5.Increasing the number of membrane-anchored SNAP-tags enhances photoactivation of mGluR2-WT. (A) Schematic representation of two BGAG28 molecules bound to a SNAP-TM variant with tandem SNAP-tags (tSNAP) as well as the endoplasmic reticulum export tag from Kir2.1 (ERE). (B) HEK293T cells expressing cytosolic tdTomato andtSNAP-EAAAK-TM-ERE labeled with the membrane impermeant dye BGAlexa647. scale bar = 10 m. (C) Summary of surface SNAP-tag levels associated with variants of SNAP-TM (one-way ANOVA, Tukey). Each data point represents a eld of many cells. (D F) Representative traces of BGAG28-induced photoactivation of mGluR2-WT when tethered to (D) tSNAP-EAAAK-TM, (E) SNAP-EAAAK-TM-ERE, and (F)tSNAP-EAAAK-TM-ERE. (G) Summary of photoactivation of SNAP-mGluR2 with BGAG0 versus mGluR2-WT with BGAG28 tethered to variants of SNAP-TM (one-way ANOVA, Tukey). (H) Photoactivation of mGluR2-WT increases with increasing levels of surface SNAP-tag.*p < 0.05,** p < 0.01,**** p < 0.0001.\nDOI:10.1021/jacs.9b02895 J. Am. Chem. Soc.XXXX, XXX, XXX XXX F\ncoexpressed with mGluR2 in the same cell. For example, dorsal root ganglion neurons coexpress mGluR2 and mGluR3.32 However, we showed previously that as a PORTL, BGAG28 activates SNAP-mGluR2 but has little or no e ect on its closest relative, the other Group II member mGluR3, or on Group III members mGluR4, 7, and 8.15 Consistent with these ndings, tSNAP-EAAAK-TM-ERE:BGAG28 had no e ect on mGluR3WT, mGluR4-WT, or mGluR8-WT (Figures S8). Furthermore, it very weakly photoactivated mGluR7-WT as atr nsagonist (8– 4% of 1 mM glutamate, n = 3;Figures S8C and F), analogous to the e cts of BGAG at SNAP-mGluR7.15 tSNAP-EAAAK-TM-ERE:BGAG28 also had no e ect on mGluR1-WT, a Group I mGluR (Figure S8). tSNAPEAAAK-TM-ERE expression was not signi ca tly di erent in cells with mGluR2-WT and any other mGluR subtype (oneway ANOVA, Tukey;Figure S8G), indicating that the selective activation of mGluR2-WT by the maPORTL is not due to di erences in surface SNAP-tag levels.\ntSNAP-EAAAK-TM-ERE:BGAG28 could also have e cts on ionotropic glutamate receptors (iGluRs). However, this would appear to be unlikely given that BGAG contains a 4- methyl-substituted glutamate, which has low a nity for iGluRs.33,34 To evaluate this, we testedtSNAP-EAAAK-TMERE:BGAG28 on selected variants from each major class of iGluR [AMPAR (GluRA1), NMDAR (GluN1/GluN2B), and KAR (GluK2)] and found there to be no e ect on any of these receptors (Figure S9). Although the maPORTL was not tested at every glutamate binding-protein, our results indicate that it preferentially photoactivates mGluR2-WT.\nSelective Photoactivation of Endogenous mGluR2 in Primary Cortical Neurons with a maPORTL.Having\nshown that the maPORTL approach works in HEK293T cells in which mGluR2 is overexpressed, we set out to determine if it would work in neurons that express mGluR2 naturally. We turned to cultured rat primary cortical neurons (CNs), which express mGluR2 endogenously.35 Antibody staining revealed that mGluR2 is distributed in a punctate manner throughout the CNs (Figure 6A), consistent with its expression pattern in ex vivopreparations of rat cortex.36 To deliver SNAP-EAAAKTM-ERE to CNs, we generated an adeno-associated virus (AAV) encoding this construct under the CAG promoter followed by the self-cleavable peptide P2A and the uorescent reporter protein mVenus (Figure 6B). AAV-infected neurons were labeled with BG-Alexa647, which indicated robust surface expression of SNAP-EAAAK-TM-ERE throughout the cell soma and neurites (Figure 6B).\nTo determine whether endogenous mGluR2 can be photoactivated, we measured the spontaneous activity of BGAG28-labeled, mVenus-expressing CNs using whole-cell, current-clamp recordings. In response to near-UV light, there was robust suppression of spontaneous ring that was reversible (Figure 6C and D), repeatable (Figure 6C and D), and bistable (Figure 6E). Photoactivation resulted in a 4– 1 mV (n = 8) hyperpolarization (Figure 6E), consistent with the e ects of endogenous Gi/o-coupled receptor activation in cortical neurons.37 This e ect was not observed in uninfected CNs labeled with BGAG28 (Figures S10A and B). Moreover, there was no e ct of BGAG28 on uninfected CNs even if the compound was left in solution (Figures S10C and D), indicating that 1 M BGAG28 in solution has too low an encounter rate with receptor to produce detectable activation.\nFigure 6.SNAP-EAAAK-TM-ERE:BGAG28 photoactivates endogenous mGluR2 in primary cortical neurons. (A) Rat primary cortical neurons (CNs), positive for the neuronal marker MAP2, express mGluR2 endogenously according to staining with an mGluR2 antibody (upper panels). Staining was not observed unless CNs were incubated with the mGluR2 antibody (lower panels). Scale bar = 15 m. (B) Schematic of the expression cassette of an AAV encoding SNAP-EAAAK-TM-ERE (upper panel). CNs expressing BG-Alexa647 labeled-SNAP-EAAAK-TM-ERE as well as the uorescent reporter mVenus (lower panels). Scale bar = 30 m. (C and D) Photoactivation of endogenous mGluR2 with SNAPEAAAK-TM-ERE:BGAG28 results in a rapid, reversible, and repeatable suppression of spontaneous ring (n = 8, one-way ANOVA, Tukey).** p < 0.01. Firing was normalized to the average ing rate for all the neurons tested under the rst pulse of visible light. Gray points and lines represent individual neurons. (E) The suppression of spontaneous ring was bistable.\nDOI:10.1021/jacs.9b02895 J. Am. Chem. Soc.XXXX, XXX, XXX XXX G\nThe e ect of SNAP-EAAAK-TM-ERE:BGAG28 on CNs was comparable to that by the mGluR2/3 agonist LY379268 (Figures S10E-G).35 Furthermore, there was no photoe ect in the presence of the mGluR2/3 antagonist LY341495 (Figures S10H and I).35 These results indicate that Group II mGluRs are the target of SNAP-EAAAK-TM-ERE:BGAG28 in CNs.\nBecause CNs coexpress mGluR2 and mGluR3,35 it is possible that the observed photoe ect is mediated by one or both of these receptors. We saw no e ect of the maPORTL on mGluR3 in HEK293T cells (Figure S8), but this may not be the case if the subcellular localization of receptor and SNAPTM is di erent in neurons. To evaluate this, we used the selective mGluR3 negative allosteric modulator (NAM) ML337, which completely abolishes mGluR3 activation (Figures S11A and B).38 ML337 had no e ect on SNAPEAAAK-TM-ERE:BGAG28-induced inhibition of CNs (Figures S11C-E), supporting the interpretation that the target of the maPORTL in CNs is indeed mGluR2.\nE ects of maPORTLs on Baseline mGluR2-WT Activation. Increasing the level of BGAG at the cell surface enhances maximal mGluR2-WT photoactivation because there is a higher availability of thecis-isomer under near-UV light. However, because a small fraction of azobenzene is incis instead oftranswhen visible light is used to rapidly turn the photoswitch o ,27 a high BGAG concentration could, in principle, increase baselinereceptor activation until the azobenzene fully relaxes into thetransstate, as it does over tens of minutes in the dark.39 This could be problematic in contexts where it is di cult to control the amount of maPORTL in a target cell typein vivo.\nTo understand this e ct, we modeled maPORTL-induced mGluR2-WT activation under visible light and near-UV light based on (i) the expression and functional e ects associated with our existing SNAP-TM variants in HEK293T cells (Figure 5H) and (ii) the assumption that the amount of BGAG28 in thecis-state is 10-fold greater under near-UV light than under visible light.27 This analysis suggested that baseline receptor activation under visible light is negligible for all SNAP-TM variants (Figures S12A and B). This included tSNAP-EAAAK-TM-ERE, which is associated with the highest surface SNAP-tag levels observed in HEK293T cells ( 5-fold greater than SNAP-TM;Figures 5H andS12B).\nWe tested this prediction by using the mGluR2 antagonist LY341495, which blocks receptor photoactivation.14 LY341495 had no e ct on HEK293T cells expressing mGluR2-WT alone, consistent with its actions as a neutral antagonist (Figures S12C and D).40 As expected, LY341495 completely blocked the activation of mGluR2-WT bytSNAPEAAAK-TM-ERE:BGAG28 under near-UV light (Figure S12E). However, it had no e ct under visible light (Figures S12E and F), indicating that baseline receptor activity is not elevated in HEK293T cells. Similarly, under visible light, LY341495 had no e ct on the spontaneous ring of CNs expressing SNAP-EAAAK-TM-ERE:BGAG28 (Figures S12G and H) .\nThe maPORTL did not increase baseline receptor activity in two di erent cellular backgrounds, even when the membrane anchor was driven by a strong expression promoter (e.g., see Figure 6B). Still, since extremely high maPORTL densities would result in baseline receptor activation (Figure S12A), we evaluated whether we could use as an maPORTL BGAG12,460,\n14 which contains a red-shifted azobenzene that transitions from itstrans-to cis-isomer under blue light and\nrelaxes back toransin the dark much more rapidly (hundreds of milliseconds).14,41,42 We rst evaluatedtSNAP-EAAAKTM-ERE:BGAG12,460 and found there to be no e ect on mGluR2-WT (Figures S13A and C), possibly because the ligand is not long enough to reach the receptor LBD. However, BGAG12,460photoactivated mGluR2-WT when tethered to a version of SNAP-TM with a longer lift peptide, SNAP(EAAAK)3-TM (Figures S13B and C). Thus, a rapidly relaxing photoswitchable ligand could be used to avoid prolonged baseline receptor activation under conditions of very high maPORTL density.\nCONCLUSION Obtaining a clear view of GPCR function is of profound importance for understanding physiology and disease. A major challenge is that many GPCRs have distinct roles in multiple tissue regions and cell types. Moreover, their temporal pro les of activation are complex, especially in the nervous system. Therefore, indiscriminately targeting GPCRs would obscure their function. To address these issues, substantial e ort has gone toward engineering methods to control receptor activity in de ned cells, locations, and times. However, these approaches (i) require modi cations that likely alter receptor function (DREADDs, optoXRs, and PORTL-gated receptors), (ii) control endogenous receptors chronically in a manner that cannot be regulated (DARTs), or (iii) are limited to controlling endogenous peptide binding-receptors with slow reversal kinetics (LumiToxins). The consequence is that, to date, there has been no method for rapidly and reversibly controlling endogenous GPCRs with cell type speci city.\nHere we devised a system that allows for selective, cell type speci c, and spatiotemporally precise control of an endogenous mGluR by tethering a photoswitchable ligand to a membraneanchored SNAP-tag, the maPORTL system. Optical control of mGluR2 by maPORTLs was optimized by tailoring the length of the linker between the SNAP attachment site and the receptor ligand, the spacer between the SNAP-tag and TM in the maPORTL s membrane anchor, the number of SNAP-tags on the membrane anchor, and the e ci ncy of delivery of the membrane anchor to the cell surface. We expect additional optimization will be necessary for receptors with di ering structural architectures. For example, whereas Family C GPCRs, such as mGluRs, bind ligands in a large extracellular clamshell LBD, Family A GPCRs bind ligands in their TMD. Thus, we predict that shorter chemical linkers and/or peptide linkers in SNAP-TM will be required to maximize optical control of these receptors.\nWe used the maPORTL approach to target mGluR2, a GPCR that naturally binds chemical ligands. However, maPORTLs can likely be expanded to other types of GPCRs, considering that azobenzene has been conjugated to structurally and functionally diverse molecules such as peptides43 and fatty acids.44,45 maPORTLs are also expected to be compatible with synthetic ligands that bind orphan GPCRs as well as with allosteric modulators and biased ligands. Overall, we expect the maPORTL approach to be generalizable to a wide variety of physiologically and clinically important membrane proteins that bind extracellular ligands, including GPCRs, ion channels, and receptor-linked enzymes.\nDOI:10.1021/jacs.9b02895 J. Am. Chem. Soc.XXXX, XXX, XXX XXX H\nASSOCIATED CONTENT *S Supporting Information The Supporting Information is available free of charge on the ACS Publications websiteat DOI: 10.1021/jacs.9b02895.\nSupplemental gures and schemes, details of chemical synthesis, and methods (PDF)\nAUTHOR INFORMATION Corresponding Author *E-mail:ehud@berkeley.edu."
    }, {
      "heading" : "ORCID",
      "text" : "Johannes Broichhagen:0000-0003-3084-6595 Dirk Trauner:0000-0002-6782-6056 Ehud Y. Isaco : 0000-0003-4775-9359 Author Contributions P.C.D. and C.S. performed the molecular biology. J.B. performed the chemical synthesis. M.V. generated the AAV. P.C.D., V.V., and Z.F. performed the experiments. E.Y.I. supervised the project. P.C.D. and E.Y.I. wrote the manuscript with input from the other authors. All authors approved the nal version of the manuscript."
    }, {
      "heading" : "Notes",
      "text" : "The authors declare no competing ancial interest.\nACKNOWLEDGMENTS This work was supported by NIH grants DA044696 to P.C.D., 2PN2EY018241 to E.Y.I. and D.T., R01 MH54137 to J.A.J., an R35 grant from the National Institute of General Medical Sciences (1 R35 GM124731) to J.L., as well as the ERC [Advanced Grant to D.T. (268795)].\nREFERENCES (1) Katritch, V.; Cherezov, V.; Stevens, R. C.Annu. Rev. Pharmacol.\nToxicol.2013, 53, 531. (2) Overington, J. P.; Al-Lazikani, B.; Hopkins, A. L.Nat. Rev. Drug Discovery2006, 5, 993. (3) Sun, F.; Zeng, J.; Jing, M.; Zhou, J.; Feng, J.; Owen, S. F.; Luo, Y.; Li, F.; Wang, H.; Yamaguchi, T.; Yong, Z.; Gao, Y.; Peng, W.; Wang, L.; Zhang, S.; Du, J.; Lin, D.; Xu, M.; Kreitzer, A. C.; Cui, G.; Li, Y.Cell2018, 174, 481. (4) Patriarchi, T.; Cho, J. R.; Merten, K.; Howe, M. W.; Marley, A.; Xiong, W. H.; Folk, R. W.; Broussard, G. J.; Liang, R.; Jang, M. J.; Zhong, H.; Dombeck, D.; von Zastrow, M.; Nimmerjahn, A.; Gradinaru, V.; Williams, J. T.; Tian, L.Science2018, 360, eaat4422 (5) Adams, P. R.; Brown, D. A.J. Physiol.1982, 332, 263. (6) Sumit, M.; Neubig, R. R.; Takayama, S.; Linderman, J. J. Integrative biology: quantitative biosciences from nano to macro2015, 7, 1378. (7) Grundmann, M.; Kostenis, E.Trends Pharmacol. Sci.2017, 38, 1110. (8) Urban, D. J.; Roth, B. L.Annu. Rev. Pharmacol. Toxicol.2015, 55, 399. (9) Airan, R. D.; Thompson, K. R.; Fenno, L. E.; Bernstein, H.; Deisseroth, K.Nature2009, 458, 1025. (10) Kim, J. M.; Hwa, J.; Garriga, P.; Reeves, P. J.; RajBhandary, U. L.; Khorana, H. G.Biochemistry2005, 44, 2284. (11) Siuda, E. R.; McCall, J. G.; Al-Hasani, R.; Shin, G.; Il Park, S.; Schmidt, M. J.; Anderson, S. L.; Planer, W. J.; Rogers, J. A.; Bruchas, M. R.Nat. Commun.2015, 6, 8480. (12) Levitz, J.; Pantoja, C.; Gaub, B.; Janovjak, H.; Reiner, A.; Hoagland, A.; Schoppik, D.; Kane, B.; Stawski, P.; Schier, A. F.; Trauner, D.; Isacoff, E. Y.Nat. Neurosci.2013, 16, 507.\n(13) Donthamsetti, P. C.; Winter, N.; Schonberger, M.; Levitz, J.; Stanley, C.; Javitch, J. A.; Isacoff, E. Y.; Trauner, D.J. Am. Chem. Soc. 2017, 139, 18522. (14) Broichhagen, J.; Levitz, J.; Sokol, K.; Leippe, P.; Konrad, D.; Isacoff, E. Y.; Trauner, D.; Damijonaitis, A.ACS Central Science2015, 1, 383. (15) Levitz, J.; Broichhagen, J.; Leippe, P.; Konrad, D.; Trauner, D.; Isacoff, E. Y.Proc. Natl. Acad. Sci. U. S. A.2017, 114, No. E3546. (16) Miwa, J. M.; Ibanez-Tallon, I.; Crabtree, G. W.; Sanchez, R.; Sali, A.; Role, L. W.; Heintz, N.euron1999, 23, 105. (17) Fortin, J. P.; Zhu, Y.; Choi, C.; Beinborn, M.; Nitabach, M. N.; Kopin, A. S.Proc. Natl. Acad. Sci. U. S. A.2009, 106, 8049. (18) Ibanez-Tallon, I.; Nitabach, M. N.Curr. Opin. Neurobiol.2012, 22, 72. (19) Shields, B. C.; Kahuno, E.; Kim, C.; Apostolides, P. F.; Brown, J.; Lindo, S.; Mensh, B. D.; Dudman, J. T.; Lavis, L. D.; Tadross, M. R. Science2017, 356, eaaj2161 (20) Schmidt, D.; Tillberg, P. W.; Chen, F.; Boyden, E. S.Nat. Commun.2014, 5, 3019. (21) Gloriam, D. E.; Fredriksson, R.; Schioth, H. B.BMC Genomics 2007, 8, 338. (22) Weinberger, D. R.Nat. Med.2007, 13, 1018. (23) Jeon, H.; Blacklow, S. C.Annu. Rev. Biochem.2005, 74, 535. (24) Conn, P. J.; Pin, J. P.Annu. Rev. Pharmacol. Toxicol.1997, 37, 205. (25) Niswender, C. M.; Conn, P. J.Annu. Rev. Pharmacol. Toxicol. 2010, 50, 295. (26) Chen, X.; Zaro, J. L.; Shen, W. C.Adv. Drug Delivery Rev.2013, 65, 1357. (27) Beharry, A. A.; Woolley, G. A.Chem. Soc. Rev.2011, 40, 4422. (28) Kniazeff, J.; Bessis, A. S.; Maurel, D.; Ansanay, H.; Prezeau, L.; Pin, J. P.Nat. Struct. Mol. Biol.2004, 11, 706. (29) Vafabakhsh, R.; Levitz, J.; Isacoff, E. Y.Nature2015, 524, 497. (30) Levitz, J.; Habrian, C.; Bharill, S.; Fu, Z.; Vafabakhsh, R.; Isacoff, E. Y.Neuron2016, 92, 143. (31) Gradinaru, V.; Thompson, K. R.; Deisseroth, K.Brain Cell Biol. 2008, 36, 129. (32) Sheahan, T. D.; Valtcheva, M. V.; McIlvried, L. A.; Pullen, M. Y.; Baranger, D. A. A.; Gereau, R. W. t.eNeuro2018, 5, ENEURO.0412-17.2018 (33) Hansen, J. J.; Nielsen, B.; Krogsgaard-Larsen, P.; Brehm, L.; Nielsen, E. O.; Curtis, D. R.J. Med. Chem.1989, 32, 2254. (34) Robinson, M. B.; Crooks, S. L.; Johnson, R. L.; Koerner, J. F. Biochemistry1985, 24, 2401. (35) Koga, K.; Iwahori, Y.; Ozaki, S.; Ohta, H.J. Neurosci. Res.2010, 88, 2252. (36) Bragina, L.; Bonifacino, T.; Bassi, S.; Milanese, M.; Bonanno, G.; Conti, F.Front Cell Neurosci2015, 9, 345. (37) van Aerde, K. I.; Qi, G.; Feldmeyer, D.Cereb Cortex2015, 25, 772. (38) Wenthur, C. J.; Morrison, R.; Felts, A. S.; Smith, K. A.; Engers, J. L.; Byers, F. W.; Daniels, J. S.; Emmitte, K. A.; Conn, P. J.; Lindsley, C. W.J. Med. Chem.2013, 56, 5208. (39) Gorostiza, P.; Volgraf, M.; Numano, R.; Szobota, S.; Trauner, D.; Isacoff, E. Y.Proc. Natl. Acad. Sci. U. S. A.2007, 104, 10865. (40) Kingston, A. E.; Ornstein, P. L.; Wright, R. A.; Johnson, B. G.; Mayne, N. G.; Burnett, J. P.; Belagaje, R.; Wu, S.; Schoepp, D. D. Neuropharmacology1998, 37, 1. (41) Kienzler, M. A.; Reiner, A.; Trautman, E.; Yoo, S.; Trauner, D.; Isacoff, E. Y.J. Am. Chem. Soc.2013, 135, 17683. (42) Carroll, E. C.; Berlin, S.; Levitz, J.; Kienzler, M. A.; Yuan, Z.; Madsen, D.; Larsen, D. S.; Isacoff, E. Y.Proc. Natl. Acad. Sci. U. S. A. 2015, 112, No. E776. (43) Behrendt, R.; Schenk, M.; Musiol, H. J.; Moroder, L.J. Pept. Sci. 1999, 5, 519. (44) Frank, J. A.; Moroni, M.; Moshourab, R.; Sumser, M.; Lewin, G. R.; Trauner, D.Nat. Commun.2015, 6, 7118. (45) Frank, J. A.; Franquelim, H. G.; Schwille, P.; Trauner, D.J. Am Chem. Soc.2016, 138, 12981.\nDOI:10.1021/jacs.9b02895 J. Am. Chem. Soc.XXXX, XXX, XXX XXX I"
    } ],
    "references" : [ ],
    "referenceMentions" : [ ],
    "year" : 0,
    "abstractText" : "G protein-coupled receptors (GPCRs) are membrane proteins that play important roles in biology. However, our understanding of their function in complex living systems is limited because we lack tools that can target individual receptors with su cient precision. State-of-th e-art approaches, including DREADDs, optoXRs, and PORTL gated-receptors, control GPCR signaling with molecular, cell type, and temporal speci city. Nonetheless, these tools are based on engineered non-native proteins that may (i) express at nonphysiological levels, (ii) localize and turnover incorrectly, and/or (iii) fail to interact with endogenous partners. Alternatively, membrane-anchored ligands (t-toxins, DARTs) target endogenous receptors with molecular and cell type speci city but cannot be turned on and o . In this study, we used a combination of chemistry, biology, and light to control endogenous metabotropic glutamate receptor 2 (mGluR2), a Family C GPCR, in primary cortical neurons. mGluR2 was rapidly, reversibly, and selectively activated with photoswitchable glutamate tethered to a genetically targeted-plasma membrane anchor (membrane anchored Photoswitchable Orthogonal Remotely Tethered Ligand; maPORTL). Photoactivation was tuned by adjusting the length of the PORTL as well as the expression level and geometry of the membrane anchor. Our ndings provide a template for controlling endogenous GPCRs with cell type speci city and high spatiotemporal precision.",
    "creator" : null
  }
}